Related Experiment Videos
[Diffuse panbronchiolitis: DPB]
Abstract:
Diffuse panbronchiolitis (DPB) is a chronic inflammatory airway disease which was lethal in the past despite combined treatment with antibiotics and the use of supportive therapies such as oxygen administration. Diagnosis of DPB is performed according to the diagnostic criteria that include major items: symptoms, existence of parasinusitis, chest radiographic findings, minor items: physical signs (coarse crackles), pulmonary functions and blood gas tests, and elevated titers of cold hemagglutinin. Pathological feature shows thickness of the wall of respiratory bronchiole with infiltration of lymphocytes, plasma cells, and foamy histiocytes expanded into the peribronchiolar area. Many of these bronchiolitis progress respiratory failure with bronchiectasis in advanced stage. Recently, DPB was interested in genetic predisposition because of high accumulation in the East Asia with the same HLA haplotype. Low-dose of erythromycin (400-600 mg/day) is a authorized therapy to improve the survival time of patients with DPB. 14-membered ring macrolides other than erythromycin also improve the survival of DPB patients.
Insights
Diffuse panbronchiolitis (DPB) is a chronic airway disease. Low-dose macrolide antibiotics, like erythromycin, significantly improve survival rates for DPB patients.
Area of Science:
- Respiratory Medicine
- Immunology
- Genetics
Context:
- Diffuse panbronchiolitis (DPB) is a chronic inflammatory airway disease.
- Historically, DPB had a poor prognosis despite conventional treatments.
- DPB is characterized by specific diagnostic criteria and pathological findings.
Purpose:
- To summarize the understanding of Diffuse Panbronchiolitis (DPB).
- To highlight diagnostic features and pathological hallmarks of DPB.
- To discuss recent insights into genetic predisposition and therapeutic advancements.
Summary:
- DPB diagnosis involves symptoms, parasinusitis, radiographic findings, physical signs, pulmonary function tests, and cold hemagglutinin titers.
- Pathology reveals thickened respiratory bronchioles with inflammatory cell infiltration.
- Genetic predisposition, particularly HLA haplotype in East Asians, is noted.
Impact:
- Low-dose erythromycin (400-600 mg/day) is an established therapy improving DPB patient survival.
- Other 14-membered ring macrolides also demonstrate efficacy in enhancing survival.
- Understanding DPB's genetics and treatment efficacy is crucial for patient outcomes.